Open surgery for acute, complicated type B dissection is associated with an operative mortality in excess of 20% and considerable morbidity including spinal cord ischaemia.
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Furthermore a mortality of 17% has recently been reported after percutaneous flap fenestration for acute type B associated malperfusion. 2 There has therefore been considerable contemporary interest in the role of TEVAR in both acute uncomplicated and complicated type B dissection.
The precise definition of acute complicated type B dissection has been recently clarified and has been defined as symptom onset of 14 days or less, with rupture, defined as haemorrhage outside the aortic wall or malperfusion, defined as visceral, renal, lower extremity or spinal cord hypoperfusion. 3 The mortality and morbidity results reported in this manuscript are excellent in comparison to historic open repair results and contemporary TEVAR results. The authors report a 30-day mortality rate of 4.4% and an overall survival of 95.6% at 1 and 3 years respectively. These are considerably better than the recently reported multicenter US data, with a 30-day mortality of 10.8% and 1-year survival of 70.6%. 3 The 3-yr survival figures are also considerably better than the 78% reported for patients medically treated and discharged from hospital alive after uncomplicated type B dissection in the IRAD database 4 and also the two-year 89% survival for stable type B dissection treated with TEVAR in the INSTEAD study. 5 There are a number of possible explanations for the better outcomes reported in current manuscript. Firstly the mean age of the patients in this study, 42 years, is much lower than the 59 years reported in the US data. 3 This may suggest genetic and environmental differences in the pathophysiology of acute, complicated type B dissection in different geographical locations. These differences should be considered when extrapolating results from one population to another.
Secondly the authors collected their data retrospectively and this may account for some discrepancies when compared to data collected systematically from five physician-sponsored investigation device exemption clinical trials.
outside the aortic boundaries. Patients with acute Type B dissection frequently present with a left pleural or mediastinal effusion and it may be difficult to differentiate haematoma from a reactive effusion on CT. Those patients reported as "impending rupture" in this study may have been considered uncomplicated by other authors.
There is no doubt that TEVAR as been an advance in the management of acute complicated type B dissection, which is reflected by the results reported in this study. The role of TEVAR in the management of the larger group of patients presenting with uncomplicated type B dissection requires further delineation. The authors treated 130 (84%) of uncomplicated type B dissections with TEVAR during this study period despite evidence from INSTEAD 5 that TEVAR offers no advantage over medical management at up to two years in this group. However we know that a proportion of patients presenting with acute uncomplicated type B dissection will go on to develop long-term complications, aortic dilatation, aneurysm formation and rupture. Ideally identifying this sub-group would allow selective early TEVAR to prevent these complications. Recent data has suggested that a false lumen diameter of greater than 22 mm in the upper descending aorta in the acute phase predicted aneurysm development with 100% sensitivity and this may be a group to target for future early intervention. 6 The endovascular techniques for dealing with acute complicated type B dissection and in particular malperfusion require further delineation. Clearly the main aim of treatment is to cover the entry tear and expand the true lumen in order to optimize visceral artery and lower extremity perfusion. In this study the authors did not perform any additional endovascular procedures to the abdominal aorta, visceral or iliac vessels. They reflect that one death from mesenteric ischaemia may have been avoidable with mesenteric artery stenting. It does appear that a proportion of patients will require additional endovascular procedures including bare metal stenting of the abdominal aorta to expand the true lumen, and mesenteric, renal or iliofemoral stents to maintain branch vessel perfusion. 7 Furthermore additional surgical extra-anatomic bypass procedures may be required to maintain left subclavian, left carotid or lower extremity perfusion. 3 A suggested algorithm for best current practice in acute complicated type B dissection would include TEVAR to cover the entry tear, rupture point and improve the true lumen perfusion with the distal extent of aortic cover to the level of the diaphram or just above the coeliac axis. Further adjunctive bare metal stenting of the infra-renal aorta to expand the true lumen or mesenteric, renal and iliac vessel stenting should be considered if completion angiography demonstrates persistent malperfusion. In addition surgical extra-anatomic bypass to maintain left subclavian perfusion and thus reduce the risk of neurological complications 8 and also to maintain lower limb blood flow may be necessary in some cases. 3 In conclusion TEVAR alone or with adjunctive endovascular techniques is rapidly becoming the treatment of choice for acute complicated type B aortic dissection with results reported in this and other contemporary studies considerably better in the short-term than for open surgery or percutaneous fenestration. The precise subset of patients with acute uncomplicated type B aortic dissection who will benefit from TEVAR remains less clear. The optimum endovascular techniques in type B dissection require further delineation and stent-graft designs specifically for dissection require further development, however as vascular specialists we are fortunate to have considerably more ammunition to deal with these complex aortic problems than in the past.
